LYEL — Lyell Immunopharma Income Statement
0.000.00%
Last trade - 00:00
- $553.21m
- $6.99m
- $0.13m
- 43
- 17
- 63
- 35
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.657 | 7.76 | 10.7 | 84.7 | 0.13 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 103 | 220 | 262 | 277 | 260 |
Operating Profit | -102 | -212 | -251 | -192 | -260 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -129 | -204 | -250 | -183 | -235 |
Net Income After Taxes | -129 | -204 | -250 | -183 | -235 |
Net Income Before Extraordinary Items | |||||
Net Income | -129 | -204 | -250 | -183 | -235 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -129 | -204 | -250 | -183 | -235 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.533 | -0.842 | -0.879 | -0.714 | -0.883 |
Dividends per Share |